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Introduction
============

Primarily indicated for treating the symptoms of anxiety and sleep disorders over short periods,[@ref1] benzodiazepines are widely prescribed in developed countries.[@ref2] [@ref3] In France, 30% of people aged 65 years and over use benzodiazepines.[@ref4] They are used by more than 20% of people aged 65 and over in Canada and Spain and by around 15% of those in Australia.[@ref5] [@ref6] [@ref7] Benzodiazepine use is less widespread but still high in elderly people in the United States and the United Kingdom.[@ref8] [@ref9] Consumption of benzodiazepines is often chronic,[@ref2] [@ref10] and many people take them for years despite the existence of good practice guidelines suggesting that the duration should be limited to a few weeks.[@ref1] [@ref10] [@ref11] [@ref12]

The short term effects of benzodiazepines on cognition are well known.[@ref13] [@ref14] [@ref15] [@ref16] They are mediated through an agonist action on receptors of γ aminobutyric acid A, a major inhibitory neurotransmitter in the brain. However, the long term adverse effects of benzodiazepines on cognition are still debated.

Studies focusing on the association between benzodiazepine use and dementia or cognitive decline in elderly people have shown conflicting results.[@ref17] Some found an increased risk of dementia or cognitive impairment in benzodiazepine users,[@ref9] [@ref18] [@ref19] [@ref20] [@ref21] whereas others were not conclusive or reported a potential protective effect.[@ref22] [@ref23] [@ref24] [@ref25] [@ref26] [@ref27] In previous studies, the timing of exposure to benzodiazepines in relation to the outcome event allowed for the possibility of reverse causation. Insomnia, depression, and anxiety (the main indications for prescribing benzodiazepines) can be prodromal symptoms of dementia.[@ref28]

Dementia is already responsible for a major societal burden worldwide. With more than 81 million cases expected in 2040,[@ref29] this burden will become even greater in the coming decades.[@ref30] As treatment options remain limited, identifying factors contributing to dementia is critical. The objective of this study was to assess the association between starting benzodiazepines and risk of subsequent dementia in a well defined population based cohort of elderly people with available follow-up of up to 20 years.

Methods
=======

Participants, design, and settings
----------------------------------

We studied participants in the prospective PAQUID cohort study, which assesses normal and pathological brain ageing. Its methods and design have been described in detail elsewhere.[@ref31] Briefly, a representative sample of 3777 community dwelling people aged 65 years and over between 1987 and 1989 were randomly selected from the general population of the Gironde and Dordogne, two administrative areas in southwest France.[@ref31] Follow-up visits took place every two or three years, and information up to the 20 year visit is available. At baseline and at each follow-up visit, trained neuropsychologists collected detailed information on personal characteristics, sociodemographics, life habits, health conditions, drug use, functional abilities, depressive symptoms, and cognition during face to face interviews.

In the study reported here, we used a cohort and a nested case-control study design. In the cohort (main) analysis, we introduced an observation period of three to five years before the start of follow-up. People were eligible to participate if they were free from dementia at the five year follow-up visit (T~5~) and reported use of benzodiazepines for the first time on that date (fig 1[](#fig1){ref-type="fig"}). Thus, participants did not use benzodiazepines at least up to the three year follow-up visit. This period was essential to allow adjustment for factors associated with starting benzodiazepines, including cognitive decline from inclusion in the PAQUID study (T~0~) to the three year follow-up visit, allaying concerns about confounding by indication, and to limit and assess the possibility of a reverse causation that was suspected in previously published studies. In the nested case-control study, we included all eligible participants in the PAQUID study.

![**Fig 1** Follow-up scheme and study design for primary cohort analysis](bils004673.f1_default){#fig1}

Exposure definition and measurement
-----------------------------------

Data on drug use, including benzodiazepine use, were collected with a standardised questionnaire at each follow-up visit. In addition, participants or their usual caregivers were asked about prescribed and non-prescribed drugs used regularly during the previous two weeks. The interviewer then validated drug use by visual inspection of the participant's medicine packs. The neuropsychologists who carried out the face to face interviews were unaware of the hypothesis of our study.

We classified all eligible participants as new benzodiazepine users or non-users according to ascertainment of exposure at T~5~ (fig 1[](#fig1){ref-type="fig"}). The exposure group comprised participants without declared benzodiazepine use at T~0~ and T~3~ and declaration of use at T~5,~ so they constituted new users of benzodiazepines between T~3~ and T~5~. In the main analysis, we did not consider subsequent exposure to benzodiazepines when estimating the association between benzodiazepine use and occurrence of dementia. Participants without any declared use at T~0~, T~3~, and T~5~ served as the reference group.

We considered all benzodiazepines and similar drugs available in France between 1988 and 2006 (alprazolam, bromazepam, chlordiazepoxide, clobazam, clonazepam, clorazepate, clotiazepam, diazepam, estazolam, flunitrazepam, loflazepate, loprazolam, lormetazepam, nitrazepam, nordazepam, prazepam, oxazepam, temazepam, tetrazepam, tofizopam, triazolam, zolpidem, and zopiclone).

Outcome definition and measurement
----------------------------------

At each follow-up, trained psychologists systematically assessed dementia on the basis of the *Diagnostic and Statistical Manual of Mental Disorders*, third edition, revised (DSM-III-R). Neurologists further examined suspected cases to confirm the diagnosis; our main outcome was neurologist confirmed dementia. As the follow-up visits were two or three years apart, we assigned the midpoint of the time interval between two follow-up visits as the index date for dementia. We determined incident cases of dementia by using information from the eight year follow-up visit (T~8~), indicating any new occurrence of dementia after baseline (T~5~).

Covariates
----------

In addition to age and sex, which are risk factors both for benzodiazepine use and for dementia, the covariates used for adjustment at the baseline for this study (T~5~) included factors considered to be associated with both benzodiazepine use and risk of dementia[@ref32] [@ref33]: educational level (schooling duration ≥7 years *v* \<7 years), marital status (single or not), wine consumption (regular consumption *v* no consumption), existence of diabetes mellitus or high blood pressure (defined according to patients' use of antidiabetic agents or antihypertensive drugs at study baseline (T~5~)), use of statins, use of platelet inhibitors or oral anticoagulants, and cognitive decline. For cognitive decline, three different tests were considered: the mini-mental state examination,[@ref34] the Benton visual retention test,[@ref35] and the Isaacs set test.[@ref36] For these three tests, we considered the difference between the scores obtained at T~3~ and at T~0~ (inclusion in the PAQUID study) as a quantitative variable. Depressive symptoms were assessed by using the Center for Epidemiologic Studies depression scale,[@ref37] categorised according to the threshold validated for the French population with a cut-off score of ≥17 for men and ≥23 for women,[@ref38] defining the presence of significant depressive symptoms.

Statistical analysis
--------------------

### Cohort, main analysis

We compared the characteristics of new users of benzodiazepines with those of non-users by using numbers and percentages for qualitative variables and median and interquartile range for quantitative variables. Figure 1[](#fig1){ref-type="fig"} details the follow-up scheme and design.

We used Kaplan-Meier curves and log-rank tests for univariable dementia-free survival analyses in exposed and non-exposed groups. We used multivariable adjusted Cox proportional hazards models to evaluate the association between new use (starting between T~3~ and T~5~) of benzodiazepines and risk of incident dementia, adjusting for potential confounding factors. The dependent variable was the occurrence of incident dementia. We adjusted the models for the following potential confounding factors (covariates): age, sex, education level, marital status, regular wine consumption, change in the mini-mental state examination between T~0~ and T~3~, and use of antidiabetic agents, antihypertensive drugs, statins, and platelet inhibitors or oral anticoagulants. As depression is thought to be a potential prodromal symptom of dementia,[@ref39] [@ref40] we did not consider depressive symptoms as a potential confounder in our main analysis. However, we included information on the presence of depressive symptoms in a sensitivity analysis because depression has also been described as a risk factor for dementia.[@ref41] We calculated person time from the date of the PAQUID five year follow-up visit (baseline of our study) to the estimated date of dementia, death, or loss to follow-up or the date of the 20 year follow-up visit, whichever came first. We verified the proportionality assumption of the Cox model by evaluating Cox-Snell residuals and found no violation.

We evaluated whether the association between benzodiazepine use and dementia was modified by age (80-84 or ≥85 *v* 70-79 years), sex, or schooling duration (≥7 *v* \<7 years). To test for statistical significant effect modification, we used the likelihood ratio test contrasting the main model with a model including appropriate interaction terms.

### Cohort, secondary analysis

To account for potential time varying effects on the association between benzodiazepine use and risk of dementia, we considered new cohorts of benzodiazepines users between the baseline of our study (PAQUID T~5~) and the following 15 years of follow-up (PAQUID T~8~ to T~20~) in a second analysis. We chose this approach as we believe that a Cox model updating information on exposure would not allow for a correct causal inference structure.[@ref42] At "baseline" and each of the four follow-up time points (T~8~, T~10~, T~13~, and T~15~), we created cohorts of new users (participants reporting benzodiazepine use for the first time at the specific follow-up visit) and followed each cohort until a censoring event occurred or until the end of the study, whichever came first. We then evaluated the association of each of these cohorts with the risk of subsequent dementia compared with participants who did not start benzodiazepines at a given time point, adjusting for the above mentioned confounders including information on depressive symptoms. The information on confounders was updated to the respective follow-up time point. Finally, we pooled the five cohorts by using a fixed effect model.

### Nested case-control analysis

Participants still followed at T~8~, without dementia before this date and with an accurate date of diagnosis of dementia, were eligible for a nested case-control analysis in the PAQUID cohort. We defined cases as participants with an incident diagnosis of dementia from T~8~ onwards, as in the cohort study. We considered all participants without a diagnosis of dementia at the time point when a case was diagnosed (index date) as controls. Among these, we randomly selected up to four controls and matched them with each case by age (±2 years) and sex. Participants could be used as controls for cases and later selected as cases if they presented with an incident diagnosis of dementia (incidence density sampling).

For the nested case-control study, we did not exclude any prevalent benzodiazepine exposure. We first classified participants as ever users (if at least one use of benzodiazepine was declared before the index date) and never users (no declaration of benzodiazepine use before index date). Among ever users, we then identified recent users (reported use at the follow-up visit preceding the index date but never before) and past users (reported use at least three visits before the index date or earlier).

We used conditional logistic regression to evaluate the association between benzodiazepine use and risk of dementia. We built two series of models, each considering one of the definitions retained for exposure to benzodiazepines. We did analyses using similar adjustment to that used for the main cohort analysis, including depressive symptoms. Models not including information on depressive symptoms showed similar associations. Potential confounding variables were measured at three follow-up time points (seven or eight years) before the index date.

We used the SAS statistical package (SAS 9.3 for Windows) for all analyses. All reported P values are two tailed, and we considered P\<0.05 to be statistically significant.

Results
=======

Cohort analysis
---------------

### Population

Of the 3777 participants in the PAQUID study, 2084 were still in active follow-up at the five year visit (T~5~, baseline for this study). We excluded 154 participants with prevalent dementia at the five year follow-up visit, 735 participants with a history of benzodiazepine use or prevalent use, and 132 with missing or questionable information on history of benzodiazepine use. The sample thus included 1063 participants free of dementia at T~5~ and without prevalent use of benzodiazepines up until T~3~ (fig 2[](#fig2){ref-type="fig"}). Among the 1063 eligible participants, 95 (8.9%) reported consumption of a benzodiazepine at study baseline (T~5~), indicating new use between T~3~ and T~5~. Table 1[](#tbl1){ref-type="table"} shows characteristics of participants included in the analysis according to benzodiazepine exposure status. Compared with non-users (n=968), new users of benzodiazepines (n=95) were more likely to have shorter school duration (66% *v* 77% with duration ≥7 years), to be single or widowed (52% *v* 41%), to have more significant depressive symptoms (16% *v* 4%), to use antihypertensive drugs (74% *v* 58%), and to use platelet inhibitors or oral anticoagulants (15% *v* 6%) and consumed wine less regularly (63% *v* 73%). No difference existed between new users of benzodiazepines and non-users in terms of age, sex, diabetes mellitus, statin use, and cognitive evolution between inclusion in the PAQUID study (T~0~) and the three year follow-up visit (T~3~).

![**Fig 2** Identification of participants from PAQUID study followed up at T~5~ (follow-up at year 5 of PAQUID study) and eligible for main cohort analysis (no dementia and no prevalent benzodiazepine use)](bils004673.f2_default){#fig2}

###### 

 Baseline characteristics of participants from PAQUID study included in cohort analysis, according to benzodiazepine use. Values are numbers (percentages) unless stated otherwise

  Characteristics                                           Benzodiazepine new users (n=95)   Benzodiazepine non-users (n=968)
  --------------------------------------------------------- --------------------------------- ----------------------------------
  Median (interquartile range) follow-up (years)            6.1 (2.2-10.4)                    6.2 (2.6-12.5)
  Dementia\*                                                30 (32)                           223 (23.0)
  Female sex                                                54 (57)                           474 (49.0)
  Age (years):                                                                                
   70-79                                                    35 (37)                           385 (39.8)
   80-84                                                    26 (27)                           240 (24.8)
   ≥85                                                      34 (36)                           343 (35.4)
  Schooling duration ≥7 years                               63 (66)                           745 (77.0)
  Single or widowed                                         49 (52)                           394 (40.7)
  Wine consumption                                          57/90 (63)                        680/932 (73.0)
  Significant depressive symptoms†                          15/93 (16)                        38/944 (4.0)
  High blood pressure‡                                      70 (74)                           562 (58.1)
  Diabetes mellitus§                                        7 (7)                             81 (8.4)
  Statin use                                                5 (5)                             36 (3.7)
  Platelet inhibitor or oral anticoagulant use              14 (15)                           55 (5.7)
  Median (interquartile range) cognitive evolution trend:                                     
   MMSE score difference between T~3~ and T~0~              0 (−1-1)                          0 (−1-1)
   Isaacs score difference between T~3~ and T~0~            0 (−2-3)                          0 (−3-3)
   Benton score difference between T~3~ and T~0~            0 (−2-1)                          0 (−1-2)

MMSE=mini-mental state examination.

\*According to *Diagnostic and Statistical Manual of Mental Disorders*, third edition, revised criteria.

†Based on Center for Epidemiologic Studies depression scale (score ≥17 for men; ≥23 for women).

‡According to use of antihypertensive drugs.

§According to use of antidiabetic agents.

### Main analysis

During the 15 year follow-up (median 6.2 (interquartile range 2.6-12.3) years), 253 (23.8%) cases of dementia were confirmed---30 (32%) in benzodiazepine users and 223 (23.0%) in non-users. Compared with non-use, new use of benzodiazepines between T~3~ and T~5~ was associated with a shorter dementia-free survival in the study population (crude survival analysis, log-rank test P=0.03) (fig 3[](#fig3){ref-type="fig"}). The incidence rate of dementia during the 15 year follow-up was 4.8 per 100 person years in the exposed group compared with 3.2 per 100 person years in the non-exposed group. Compared with participants who did not report use of benzodiazepines at baseline (n=968), starting benzodiazepines between T~3~ and T~5~ (n=95) was associated with a significantly increased risk of dementia (hazard ratio 1.60, 95% confidence interval 1.08 to 2.38), after adjustment for potential confounding factors. When further adjusted for depressive symptoms, this result was unchanged (hazard ratio 1.62, 1.08 to 2.43) (table 2[](#tbl2){ref-type="table"}). Use of the Isaacs or the Benton test instead of the mini-mental state examination yielded similar results (hazard ratios 1.67 and 1.68).

![**Fig 3** Dementia-free survival in PAQUID study, in new benzodiazepine users and non-users at baseline (T~5~)](bils004673.f3_default){#fig3}

###### 

 Association between new use of benzodiazepine with incident dementia in PAQUID study. Values are numbers (percentages) unless stated otherwise

                                    Incident dementia   No dementia during follow-up   Hazard ratio (95%CI)
  --------------------------------- ------------------- ------------------------------ ----------------------
  **Analysis adjusted for age\***   **(n=253)**         **(n=810)**                    
  Benzodiazepine non-users          223 (88)            745 (92.0)                     1.00
  Benzodiazepine new users          30 (12)             65 (8.0)                       1.59 (1.09 to 2.34)
  **Main analysis†**                **(n=240)**         **(n=766)**                    
  Benzodiazepine non-users          211 (88)            708 (92.4)                     1.00
  Benzodiazepine new users          29 (12)             58 (7.6)                       1.60 (1.08 to 2.38)
  **Complementary analysis†‡**      **(n=231)**         **(n=752)**                    
  Benzodiazepine non-users          203 (88)            695 (92.4)                     1.00
  Benzodiazepine new users          28 (12)             57 (7.6)                       1.62 (1.08 to 2.43)

\*At baseline (T~5~).

†Adjusted for age, sex, schooling duration, singleness, wine consumption, use of antihypertensive drugs, use of antidiabetic agents, use of statins, use of platelet inhibitors or oral anticoagulants, and mini-mental state examination evolution between inclusion (T~0~) and three year follow-up visit (T~3~).

‡Adjusted for significant depressive symptoms according Center for Epidemiologic Studies depression scale (score ≥17 for men; ≥23 for women) at baseline (T~5~).

Out of the 1063 participants included, 57 (5%) had missing values for at least one of the 10 variables used for adjustment in the main analysis---8 (8%) in the exposed group and 49 (5%) in the non-exposed group (P=0.17). We did not find any significant effect modification of the association between starting benzodiazepines and incident dementia by age (P for interaction=0.10), sex (P for interaction=0.23), or duration of schooling (P for interaction=0.43).

### Secondary analysis

In the secondary analysis, we created benzodiazepine new user and non-user cohorts at baseline (T~5~) and the follow-up time points T~8~, T~10~, T~13~, and T~15~. This added a total of 116 new users during follow-up to the 95 new users at baseline. We then pooled the association between new use of benzodiazepine and risk of incident dementia across the five cohorts (baseline and four follow-up cohorts) by using a fixed effect model. The pooled multivariable adjusted hazard ratio of dementia was 1.40 (1.06 to 1.85). Additional control for symptoms of depression did not alter this result (hazard ratio 1.46, 1.10 to 1.94) (fig 4[](#fig4){ref-type="fig"}).

![**Fig 4** Pooled associations between new benzodiazepine use at follow-up years 5 (cohort T~5~), 8 (cohort T~8~), 10 (cohort T~10~), 13 (cohort T~13~), and 15 (cohort T~15~) and risk of subsequent dementia. Results adjusted for age, sex, schooling duration, singleness, wine consumption, use of antihypertensive drugs, use of antidiabetic agents, use of statins, use of platelet inhibitors or oral anticoagulants, depressive symptoms, and mini-mental state examination evolution between inclusion (T~0~) and 3 year follow-up visit (T~3~)](bils004673.f4_default){#fig4}

Nested case-control analysis
----------------------------

One thousand six hundred and thirty-three participants still followed at T~8~ were eligible for the nested case-control analysis (fig 5[](#fig5){ref-type="fig"}). We identified 467 cases of dementia and 1810 controls for the nested case-control analysis (which did not exclude prevalent users at T~0~ or T~3~, unlike in the cohort analysis). Table 3[](#tbl3){ref-type="table"} shows characteristics of cases and controls. Ever users had an increased risk of dementia (adjusted odds ratio 1.55, 1.24 to 1.95). We found similar associations in past users (adjusted odds ratio 1.56, 1.23 to 1.98) and recent users (adjusted odds ratio 1.48, 0.83 to 2.63), but the result was significant only for past users (table 4[](#tbl4){ref-type="table"}).

![**Fig 5** Identification of participants from PAQUID study eligible for nested case-control analysis](bils004673.f5_default){#fig5}

###### 

 Characteristics of cases and controls included in nested case-control study from PAQUID study. Values are numbers (percentages)

  Characteristics                                Cases (n=467)   Controls (n=1810)
  ---------------------------------------------- --------------- -------------------
  Benzodiazepine ever users                      233 (50)        741 (40.9)
  Benzodiazepine recent users                    17 (4)          52 (2.9)
  Benzodiazepine past users                      216 (46)        689 (38.1)
  Schooling duration ≥7 years                    298 (64)        1339 (74.0)
  Single or widowed                              240/456 (53)    1012/1784 (56.7)
  Wine consumption                               267/454 (59)    1066/1777 (60.0)
  Significant depressive symptoms\*              46/450 (10)     153/1778 (8.6)
  High blood pressure†                           274/456 (60)    1125/1784 (63.1)
  Diabetes mellitus‡                             29/456 (6)      96/1784 (5.4)
  Statin use                                     26/456 (6)      73/1784 (4.1)
  Platelet inhibitor or oral anticoagulant use   32/456 (7)      164/1784 (9.2)

\*Based on Center for Epidemiologic Studies depression scale (score ≥17 for men; ≥23 for women).

†According to use of antihypertensive drugs.

‡According to use of antidiabetic agents.

###### 

 Risk of dementia associated with benzodiazepine use in nested case control study of 1633 elderly people form PAQUID study. Values are numbers (percentages) unless stated otherwise

                                 Cases      Controls     Odds ratio (95%CI) by drug use
  ------------------------------ ---------- ------------ --------------------------------
  **Ever use analysis**                                  
  Univariate analysis\*:         (n=467)    (n=1810)     
   Benzodiazepine non-users      175 (37)   845 (46.7)   1.00
   Benzodiazepine ever users     233 (50)   741 (40.9)   1.54 (1.24 to 1.93)
   Missing exposure              59 (13)    224 (12.4)   1.30 (0.93 to 1.81)
  Multivariable analysis\*†:     (n=449)    (n=1771)     
   Benzodiazepine non-users      174 (39)   844 (47.7)   1.00
   Benzodiazepine ever users     233 (52)   738 (41.7)   1.55 (1.24 to 1.95)
   Missing exposure              42 (9)     189 (10.7)   1.04 (0.71 to 1.53)
  **Recent/past use analysis**                           
  Univariate analysis\*:         (n=467)    (n=1810)     
   Benzodiazepine non-users      175 (37)   845 (46.7)   1.00
   Benzodiazepine recent users   17 (4)     52 (2.9)     1.58 (0.90 to 2.78)
   Benzodiazepine past users     216 (46)   689 (38.1)   1.54 (1.23 to 1.93)
   Missing exposure              59 (13)    224 (12.4)   1.30 (0.93 to 1.81)
  Multivariable analysis\*†:     (n=449)    (n=1771)     
   Benzodiazepine non-users      174 (39)   844 (47.7)   1.00
   Benzodiazepine recent users   17 (4)     52 (2.9)     1.48 (0.83 to 2.63)
   Benzodiazepine past users     216 (48)   686 (38.7)   1.56 (1.23 to 1.98)
   Missing exposure              42 (9)     189 (10.7)   1.04 (0.71 to 1.53)

\*Matched for age and sex.

†Adjusted for schooling duration, singleness, wine consumption, use of antihypertensive drugs, use of antidiabetic agents, use of statins, use of platelet inhibitors or oral anticoagulants, and significant depressive symptoms according to Center for Epidemiologic Studies depression scale (score ≥17 for men; ≥23 for women), 7 or 8 years before index date.

Discussion
==========

In this large, prospective, population based study of elderly people who were free of dementia and did not use benzodiazepines until at least the third year of follow-up, new use of benzodiazepines was associated with a significant, approximately 50% increase in the risk of dementia. This result remained stable after adjustment for potential confounding factors, including cognitive decline before starting benzodiazepine and clinically significant symptoms of depression. It also remained robust when we pooled five cohorts of new benzodiazepine users throughout the 15 year follow-up period and in a complementary nested case-control study.

Comparison with other studies
-----------------------------

Our findings are consistent with three previous case-control studies that also showed an increased risk of dementia in benzodiazepine users. Two of them were done in Taiwan using health insurance data of people aged 45 years and older and found an increased risk of dementia in chronic users (\>6 months) (adjusted odds ratio 1.24, 1.01 to 1.53)[@ref18] and current users (adjusted odds ratio 2.71, 2.46 to 2.99).[@ref19] A nested case-control study among French people aged 65 and over showed an increased risk of dementia in former users (adjusted odds ratio 2.3, 1.2 to 4.5).[@ref21] However, the maximum length of follow-up in those studies was eight years,[@ref18] [@ref19] [@ref21] raising concerns that prodomal symptoms of dementia could have influenced benzodiazepine use.[@ref28] The results of the Caerphilly prospective cohort showed an increase in the risk of dementia in people who ever used benzodiazepines (adjusted odds ratio 2.94, 1.16 to 7.46) up to 22 years of follow-up. The results of that study also suggested that the potential excess risk of dementia associated with benzodiazepine use may apply to a population with low benzodiazepine consumption. However, benzodiazepine users could not be classified as new starters and the sample size was too small to allow for meaningful subgroup analyses (for example, 12 participants had exposure of four years or more among the 93 with dementia).[@ref9]

In contrast to our results, two studies did not find an increased risk of dementia among elderly people using benzodiazepines. The results of one (case-control) study, however, showed a similar effect estimate to ours, but this did not reach statistical significance (adjusted odds ratio 1.5, 0.6 to 3.4), probably owing to the small sample size.[@ref22] The other (cohort) study, suggested a beneficial effect of benzodiazepine use on dementia (unadjusted odds ratio 0.34) but considered past users as members of the reference group, which could have biased the results.[@ref27] A more detailed comparison of studies that have explored the potential association between benzodiazepine use and the risk of dementia is summarised in the supplementary (web extra) table.

Our study included a markedly larger number of participants than did the previous long term study on the topic,[@ref9] and we incorporated a run-in time of at least three years to allow adjustment for factors associated with starting benzodiazepines, thereby reducing the possibility of reverse causation. In that sense, an excess risk observed during the early phase of exposure could be congruent with a reverse causation bias, which would not be the case if the increase in risk appeared long after the start of exposure.

Benzodiazepines could also be seen as an early risk marker for dementia that might highlight a particular at risk background in patients, but without playing any causal role in the occurrence of the disease. For example, persistent anxiety in middle age has been shown to be associated with a greater risk of dementia in elderly people.[@ref43] Hence, benzodiazepine use may be a marker of this scenario and might help to identify people at increased risk of, and not already on the causal pathway leading to, dementia. However, in our study, two observations argue against this hypothesis: the strength of association did not increase across the five cohorts of new users (which would be expected in the event of reverse causation, as the time from benzodiazepine use to development of dementia is shorter), and the association between new use of benzodiazepines and dementia increased after about seven years of follow-up (fig 3[](#fig3){ref-type="fig"}). However, reverse causation cannot be entirely ruled out as an alternative explanation of our findings.

Strengths and limitations
-------------------------

This study has several strengths. Firstly, it was based on a long follow-up period allowing assessment of the delayed effects of exposure to benzodiazepine, which was not possible in previous studies (except one[@ref9]). Secondly, we defined incident dementia by applying validated criteria (DSM-III-R) ascertained by senior neurologists who were blind to the study hypothesis. Thirdly, trained interviewers prospectively recorded and validated data on drug exposure by visual inspection of the patients' medicine. Fourthly, restricting analyses to new users of benzodiazepine after at least a three to five year "run-in" period allowed us to adjust for factors strongly associated with starting benzodiazepines. Lastly, the study was carried out in a large representative cohort of elderly participants,[@ref31] with adjustment on a large number of potential confounders of the benzodiazepine-dementia association.[@ref2] [@ref3] [@ref32] [@ref33]

The study also has several limitations. Firstly, we had a limited number of new users at baseline (n=95), thereby limiting the power for subgroup analyses and ruling out the possibility of assessing individual benzodiazepines. However, the literature contains no suggestion that specific benzodiazepines have differential effects on cognition or dementia.[@ref23] Secondly, we could not adjust separately for anxiety and sleep disorders, both putative dementia prodromes, owing to the lack of specific measurement of these symptoms in the PAQUID programme. However, the Center for Epidemiologic Studies depression scale includes these items in computation of its global score, and entering three separate scores in the model could have raised a concern about colinearity, as depressive symptoms are often associated with sleep disorders and anxiety, especially in elderly people. Lastly, people who had missing information for benzodiazepine use during the three to five year run-in period of this study were not included, as they could not be ascertained for exposure status. As these missing data were linked to unperformed follow-up, which has been related to subsequent higher risk of dementia,[@ref44] a potential selection bias could have occurred. However, these ineligible participants had a lower schooling level and were more likely to live alone, two factors known to increase the risk of both benzodiazepine use and incident dementia. Therefore, a potential selection bias due to exclusion of people with missing information for exposure before the index date would have tended to decrease the strength of the association. The disparity in the incidence of dementia over a comparable time window was similar to that seen in the participants included.

Implication for clinical practice and public health
---------------------------------------------------

Benzodiazepines remain useful for the treatment of acute anxiety states and transient insomnia.[@ref45] [@ref46] However, increasing evidence shows that their use may induce adverse outcomes, mainly in elderly people, such as serious falls and fall related fractures.[@ref47] [@ref48] Our data add to the accumulating evidence that use of benzodiazepines is associated with increased risk of dementia, which, given the high and often chronic consumption of these drugs in many countries,[@ref10] [@ref49] [@ref50] would constitute a substantial public health concern. Therefore, physicians should carefully assess the expected benefits of the use of benzodiazepines in the light of these adverse effects and, whenever possible, limit prescription to a few weeks as recommended by the good practice guidelines.[@ref1] In particular, uncontrolled chronic use of benzodiazepines in elderly people should be cautioned against.

Unanswered questions and future research
----------------------------------------

Further research should explore whether long term use of benzodiazepines in people under 65 is also associated with an increased risk of dementia and should study possible correlations between dosage or cumulative length of exposure and dementia.

Conclusion
----------

The findings of this large prospective population based study show that new use of benzodiazepines is associated with an approximately 50% increase in the risk of dementia. The results remained robust after control for potential confounders, in pooled analysis across the follow-up time, and in a nested case-control study. Considering the extent to which benzodiazepines are now prescribed, physicians and regulatory agencies should consider the increasing evidence of the potential adverse effects of this drug class for the general population.

### What is already known on this topic

1.  Prescription of benzodiazepines in elderly people is widespread and often chronic in many developed countries, regardless of good practice guidelines

2.  Benzodiazepines can have delayed adverse effects on cognition (cognitive decline and dementia), as reported in several case-control studies and a few cohort studies

### What this study adds

1.  Benzodiazepine exposure was associated with dementia, even after a long follow-up period

2.  Adjustment for factors strongly associated with starting benzodiazepines or considered to be markers for a prodrome of early dementia did not alter the association
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